Current opinion in organ transplantation · 2026
Updates in pediatric kidney transplantation.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Engen Rachel M
Аннотация
PURPOSE OF REVIEW: This manuscript highlights key areas of recent pediatric nephrology research that may be relevant to clinical practice.
RECENT FINDINGS: Recent reviews of registry data have emphasized the long-term harms of even limited dialysis exposure in children, while studies of 'nonideal' donor kidneys in children have shown positive outcomes. New observational research suggests a benefit to thromboprophylaxis and aggressive fluid management immediately posttransplant, though the best prescriptions remain unclear. Belatacept and letermovir are emerging options for immunosuppression and CMV prophylaxis, respectively, that may have fewer side effects compared to standard of care; interventional studies of these drugs are ongoing.
CONCLUSION: Transplant teams should consider using a broader range of donor organs in select pediatric patients. Further interventional research on peritransplant thromboprophylaxis and fluid management is needed to optimize management strategies. The completion of ongoing belatacept and letermovir trials have the potential to substantially alter posttransplant standards of care.
RECENT FINDINGS: Recent reviews of registry data have emphasized the long-term harms of even limited dialysis exposure in children, while studies of 'nonideal' donor kidneys in children have shown positive outcomes. New observational research suggests a benefit to thromboprophylaxis and aggressive fluid management immediately posttransplant, though the best prescriptions remain unclear. Belatacept and letermovir are emerging options for immunosuppression and CMV prophylaxis, respectively, that may have fewer side effects compared to standard of care; interventional studies of these drugs are ongoing.
CONCLUSION: Transplant teams should consider using a broader range of donor organs in select pediatric patients. Further interventional research on peritransplant thromboprophylaxis and fluid management is needed to optimize management strategies. The completion of ongoing belatacept and letermovir trials have the potential to substantially alter posttransplant standards of care.